亚洲知识产权资讯网为知识产权业界提供一个一站式网上交易平台，协助业界发掘知识产权贸易商机，并与环球知识产权业界建立联系。无论你是知识产权拥有者正在出售您的知识产权，或是制造商需要购买技术以提高操作效能，又或是知识产权配套服务供应商，你将会从本网站发掘到有用的知识产权贸易资讯。

返回搜索结果

A Novel Class of Exceptionally Potent HIV-1 Protease Inhibitors

总结: Researchers at Purdue University have synthesized a series of exceptionally potent inhibitors for HIV-1 protease, which have been documented as an effective strategy for the treatment of AIDS and HIV. These compounds represent a novel class of HIV-1 protease inhibitors, which have proven to be up to 20-fold more potent than other protease inhibitors on the market.

技术优势: Far more potent than other protease inhibitors on the marketGreater potency will significantly reduce dosage requirements Treatment of multidrug-resistant strain of HIV

*Background: As reported by the World Health Organization (WHO), globally, there were 35.3 million people living with HIV/AIDS in 2012, a number that has been growing due to the increased availability of antiviral treatments. After peaking from 1997 to 2011, the incidence rate has declined nearly 30 percent from 3.5 million to 2.5 million. Within the last 10 years, the availability of antiretroviral therapy and the combination of at least three antiretroviral drugs within low- and middle-income regions has increased nearly 20-fold. In 2010, the global market for HIV/AIDS treatment was valued close to $14 billion and growing, with Gilead Sciences' market-leading protease inhibitor, Atripla, generating revenue of $3.22 billion in 2011.

*Web Links: Purdue Office of Technology CommercializationPurdueInnovation and EntrepreneurshipArun GhoshGhosh GroupPurdue Chemistry

欲了解更多信息，请点击这里